The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population- an updated meta-analysis

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Shi, LiGen ^a   Pu, JiaLi ^b   Xu, Liang ^a   Malaguit, Jay ^c   Zhang, Jianmin ^a   Chen, Sheng ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute Phase; Chronic phase; Cilostazol; Meta analysis; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; PLACEBO; ANTITHROMBOCYTIC AGENT; TETRAZOLE DERIVATIVE;

ARTICLE; ASIAN; BRAIN ISCHEMIA; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; EMBASE; EVALUATION AND FOLLOW UP; GRADING OF RECOMMENDATIONS ASSESSMENT DEVELOPMENT AND EVALUATION; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; SECONDARY PREVENTION; SYSTEMATIC REVIEW; ACUTE DISEASE; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN HEMORRHAGE; CEREBRAL INFARCTION; CHEMICALLY INDUCED; CHRONIC DISEASE; STROKE; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME;

ACUTE DISEASE; ASIAN CONTINENTAL ANCESTRY GROUP; ASPIRIN; CEREBRAL HEMORRHAGE; CEREBRAL INFARCTION; CHRONIC DISEASE; HUMANS; PLATELET AGGREGATION INHIBITORS; SECONDARY PREVENTION; STROKE; SUBARACHNOID HEMORRHAGE; TETRAZOLES; TREATMENT OUTCOME;

EID: 84924019425     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-014-0251-7     Document Type: Article

References (36)

1. Murray CJ, Lopez AD: Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 1997, 349:1436-1442.
2. Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, Li Z, Zhang W, Ding M, Gao X, Fan D, Zeng J, Wong K, Lu C, Xiao J, Yao C: Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008, 7:494-499.
3. Pendlebury ST, Rothwell PM: Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009, 8:1006-1018.
4. Guo JJ, Xu E, Lin QY, Zeng GL, Xie HF: Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. Neurosci Bull 2009, 25:383-390.
5. Estol CJ, Bath PM, Gorelick PB, Cotton D, Martin RH, Committee PRP, Investigators PR: Differences in ischemic and hemorrhagic recurrence rates among race-ethnic groups in the PRoFESS secondary stroke prevention trial. Int J Stroke 2014, Suppl A100:43-47.
6. He J, Whelton PK, Vu B, Klag MJ: Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998, 280:1930-1935.
7. Jaspers Focks J, Tielemans MM, van Rossum LG, Eikendal T, Brouwer MA, Jansen JB, Laheij RJ, Verheugt FW, van Oijen MG: Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin. Neth Heart J 2014, 22:107-112.
8. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, Hidaka H: Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 2000, 59:347-356.
9. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C: Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010, 9:959-968.
10. Lee YS, Bae HJ, Kang DW, Lee SH, Yu K, Park JM, Cho YJ, Hong KS, Kim DE, Kwon SU, Lee KB, Rha JH, Koo J, Han MG, Lee SJ, Lee JH, Jung SW, Lee BC, Kim JS: Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. Cerebrovasc Dis 2011, 32:65-71.
11. Dinicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH, Bangalore S, Messerli FH: Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. Am J Cardiol 2013, 112:1230-1234.
12. Qian Y, Bi Q: Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. Eur J Med Res 2013, 18:53.
13. Buras JA, Reenstra WR: Endothelial-neutrophil interactions during ischemia and reperfusion injury: basic mechanisms of hyperbaric oxygen. Neurol Res 2007, 29:127-131.
14. Caplan LR: Worsening in ischemic stroke patients: is it time for a new strategy? Stroke 2002, 33:1443-1445.
15. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y: Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000, 9:147-157.
16. Shimizu H, Tominaga T, Ogawa A, Kayama T, Mizoi K, Saito K, Terayama Y, Ogasawara K, Mori E: Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial. J Stroke Cerebrovasc Dis 2013, 22:449-456.
17. Brozek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW, Phillips B, Lelgemann M, Lethaby A, Bousquet J, Guyatt GH, Schunemann HJ, Group GW: Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 2009, 64:669-677.
18. Brozek JL, Akl EA, Jaeschke R, Lang DM, Bossuyt P, Glasziou P, Helfand M, Ueffing E, Alonso-Coello P, Meerpohl J, Phillips B, Horvath AR, Bousquet J, Guyatt GH, Schunemann HJ: Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy 2009, 64:1109-1116.
19. Brozek JL, Akl EA, Compalati E, Kreis J, Terracciano L, Fiocchi A, Ueffing E, Andrews J, Alonso-Coello P, Meerpohl JJ, Lang DM, Jaeschke R, Williams JW, Jr., Phillips B, Lethaby A, Bossuyt P, Glasziou P, Helfand M, Watine J, Afilalo M, Welch V, Montedori A, Abraha I, Horvath AR, Bousquet J, Guyatt GH, Schunemann HJ: Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy 2011, 66:588-595.
20. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
21. Mohr JP, Caplan LR, Melski JW, Goldstein RJ, Duncan GW, Kistler JP, Pessin MS, Bleich HL: The Harvard Cooperative Stroke Registry: a prospective registry. Neurology 1978, 28:754-762.
22. Marti-Vilalta JL, Arboix A: The Barcelona stroke registry. Eur Neurol 1999, 41:135-142.
23. Yamamoto H, Bogousslavsky J, van Melle G: Different predictors of neurological worsening in different causes of stroke. Arch Neurol 1998, 55:481-486.
24. Arboix A, Marti-Vilalta JL, Garcia JH: Clinical study of 227 patients with lacunar infarcts. Stroke 1990, 21:842-847.
25. Norrving B, Cronqvist S: Clinical and radiologic features of lacunar versus nonlacunar minor stroke. Stroke 1989, 20:59-64.
26. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006, 113:e409-e449.
27. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1-13.
28. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755-1762.
29. Kasahara Y, Nakagomi T, Matsuyama T, Stern D, Taguchi A: Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. Stroke 2012, 43:499-506.
30. Oyama N, Yagita Y, Kawamura M, Sugiyama Y, Terasaki Y, Omura-Matsuoka E, Sasaki T, Kitagawa K: Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats. Stroke 2011, 42:2571-2577.
31. Nakamura T, Tsuruta S, Uchiyama S: Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. J Neurol Sci 2012, 313:22-26.
32. Lee JH, Cha JK, Lee SJ, Ha SW, Kwon SU: Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. Eur J Neurol 2010, 17:434-442.
33. Paciaroni M, Bogousslavsky J: Primary and secondary prevention of ischemic stroke. Eur Neurol 2010, 63:267-278.
34. Feldmann E, Daneault N, Kwan E, Ho KJ, Pessin MS, Langenberg P, Caplan LR: Chinese-white differences in the distribution of occlusive cerebrovascular disease. Neurology 1990, 40:1541-1545.
35. Inzitari D, Hachinski VC, Taylor DW, Barnett HJ: Racial differences in the anterior circulation in cerebrovascular disease. How much can be explained by risk factors? Arch Neurol 1990, 47:1080-1084.
36. Waddy SP, Cotsonis G, Lynn MJ, Frankel MR, Chaturvedi S, Williams JE, Chimowitz M: Racial differences in vascular risk factors and outcomes of patients with intracranial atherosclerotic arterial stenosis. Stroke 2009, 40:719-725.